[1] CERNAK V,OUDE LANSINK-HARTGRING A,VAN DEN HEUVEL E R,et al.Incidence of massive transfusion and overall transfusion requirements during lung transplantation over a 25-year period[J].J Cardiothorac Vasc Anesth,2019,33(9):2478-2486. [2] MCMAHON T J,PRYBYLOWSKI A C.Anemia in the patient with chronic lung disease[M]//Management of Anemia.New York,NY:Springer New York,2017:143-155. [3] 张稷,杨航,黄健.中国肺移植受者选择与术前评估技术规范(2019版)[J].中华移植杂志(电子版),2019,13(2):81-86. [4] PENA J J,BOTTIGER B A,MILTIADES A N.Perioperative management of bleeding and transfusion for lung transplantation[J].Semin Cardiothorac Vasc Anesth,2020,24(1):74-83. [5] RUBINGER D A,CAHILL C,NGO A,et al.Preoperative Anemia management:what's new in 2020?[J].Curr Anesthesiol Rep,2020,10(2):166-175. [6] HEINRICH S,LOOP T.Preoperative treatment of Anemia-could an ultra-short-term multimodal approach be beneficial for patients undergoing lung surgery?[J].J Thorac Dis,2019,11(Suppl 15):S1913-S1915. [7] HAYES D JR,TUMIN D,YATES A R,et al.Transfusion with packed red blood cells while awaiting lung transplantation is associated with reduced survival after lung transplantation[J].Clin Transplant,2016,30(12):1545-1551. [8] FOOD AND DRUG ADMINISTRATION.FDA Drug Safety Communication:Erythropoiesis-Stimulating Agents(ESAs):Procrit, Epogen and Aranesp.2010.https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-erythropoiesis-stimulating-agents-esas-procrit-epogen-and-aranesp. [9] BOSANQUET J P,WITT C A,BEMISS B C,et al.The impact of pre-transplant allosensitization on outcomes after lung transplantation[J].J Heart Lung Transplant,2015,34(11):1415-1422. [10] TINCKAM K J,KESHAVJEE S,CHAPARRO C,et al.Survival in sensitized lung transplant recipients with perioperative desensitization[J].Am J Transplant,2015,15(2):417-426. [11] NAKAMURA T,USHIGOME H,SHIROUZU T,et al.Donor-specific anti-HLA antibodies in organ transplantation:transition from serum DSA to intra-graft DSA[M]//Human Leukocyte Antigen (HLA).2019. [12] KAYAWAKE H,CHEN-YOSHIKAWA T F,GOCHI F,et al.Postoperative outcomes of lung transplant recipients with preformed donor-specific antibodies[J].Interact Cardiovasc Thorac Surg,2021,32(4):616-624. [13] HIRANO R,NAMAZUDA K,HIRATA N.Double filtration plasmapheresis:Review of current clinical applications[J].Ther Apher Dial,2021,25(2):145-151. [14] SMITH I,PEARSE B L,FAULKE D J,et al.Targeted bleeding management reduces the requirements for blood component therapy in lung transplant recipients[J].J Cardiothorac Vasc Anesth,2017,31(2):426-433. [15] KOZEK-LANGENECKER S A,AHMED A B,AFSHARI A,et al.Management of severe perioperative bleeding:guidelines from the European Society of Anaesthesiology First update 2016[J].Eur J Anaesthesiol,2017,34(6):332-395. [16] NORTHROP M S,SIDONIO R F,PHILLIPS S E,et al.The use of an extracorporeal membrane oxygenation anticoagulation laboratory protocol is associated with decreased blood product use, decreased hemorrhagic complications,and increased circuit life[J].Pediatr Crit Care Med,2015,16(1):66-74. [17] ONG L P,THOMPSON E,SACHDEVA A,et al.Allogeneic blood transfusion in bilateral lung transplantation:impact on early function and mortality[J].Eur J Cardiothorac Surg,2016,49(2):668-674;discussion674. [18] WEBER D,COTTINI S R,LOCHER P,et al.Association of intraoperative transfusion of blood products with mortality in lung transplant recipients[J].Perioper Med(Lond),2013,2(1):20. [19] 陈静瑜,毛文君,杨柯佳,等.肺移植围手术期体外膜肺氧合应用指南(2019版)[J].器官移植,2019,10(4):402-409. [20] TEMAN N R,XIAO J T,TRIBBLE C G,et al.Median sternotomy for lung transplantation:techniques and advantages[J].Heart Surg Forum,2017,20(3):E089-E091. [21] MARCZIN N,POPOV A F,ZYCH B,et al.Outcomes of minimally invasive lung transplantation in a single centre:the routine approach for the future or do we still need clamshell incision?[J].Interact Cardiovasc Thorac Surg,2016,22(5):537-545. [22] 赵晋,陈静瑜,刘东,等.肺移植治疗终末期慢性阻塞性肺病的术式选择[J].中华器官移植杂志,2018,39(12):757-760. [23] SLAMA A,TAUBE C,KAMLER M,et al.Lung volume reduction followed by lung transplantation-considerations on selection criteria and outcome[J].J Thorac Dis,2018,10(Suppl 27):S3366-S3375. [24] FRANK S M,SIKORSKI R A,KONIG G,et al.Clinical utility of autologous salvaged blood:a review[J].J Gastrointest Surg,2020,24(2):464-472. [25] SCHEININ S A,MAJUMDAR T,FOREST S M,et al.Lung transplantation in Jehovah's witness patients-A single center experience[J].J Heart Lung Transplant,2018,37(4):S239. [26] FOUKANELI T,KERR P,BOLTON-MAGGS P H B,et al.Guidelines on the use of irradiated blood components[J].Br J Haematol,2020,191(5):704-724. [27] 卫栋,范立,班乐.中国肺移植术后并发症诊疗和随访技术规范(2019版)[J].中华移植杂志(电子版),2019,13(2):99-108. [28] YEO H J,KIM D H,JEON D,et al.Low-dose heparin during extracorporeal membrane oxygenation treatment in adults[J].Intensive Care Med,2015,41(11):2020-2021. [29] EXTRACORPOREAL LIFE SUPPORT ORGANIZATION (ELSO).Guidelines for Adult Respiratory Failure[EB/OL].2017.https://www.elso.org/Portals/0/ELSO%20Guidelines%20For%20Adult%20Respiratory%20Failure%201_4.pdf. [30] KOSTER A,FARAONI D,LEVY J H.Antifibrinolytic therapy for cardiac surgery:an update[J].Anesthesiology,2015,123(1):214-221. [31] PAGANO D,MILOJEVIC M,MEESTERS M I,et al.2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery[J].Eur J Cardiothorac Surg,2018,53(1):79-111. [32] ROSSAINT R,BOUILLON B,CERNY V,et al.The European guideline on management of major bleeding and coagulopathy following trauma:fourth edition[J].Crit Care,2016,20:100. [33] ISLAM A K,SINHA N,DEVOS J M,et al.Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation[J].Clin Transplant,2017,31(8). [34] HUDDLESTON S J,JACKSON S,KANE K,et al.Separate effect of perioperative recombinant human factor VIIa administration and packed red blood cell transfusions on midterm survival in lung transplantation recipients[J].J Cardiothorac Vasc Anesth,2020,34(11):3013-3020. [35] SCHMITZER M,WINTER H,KNEIDINGER N,et al.Persistence of de novo donor specific HLA-Antibodies after lung transplantation:a potential marker of decreased patient survival[J].HLA,2018. [36] KUMMROW M,HIHO S,HUDSON F,et al.Transfer of donor anti-HLA antibody expression to multiple transplant recipients:a potential variant of the passenger lymphocyte syndrome?[J].Am J Transplant,2019,19(5):1577-1581. [37] DE BRUIJN S,PHILIPSE E,COUTTENYE M M,et al.Passenger lymphocyte syndrome (PLS):a single-center retrospective analysis of minor ABO-incompatible liver transplants[J].J Clin Transl Hepatol,2017,5(1):9-15. [38] DYKES A,SMALLWOOD D,KOTSIMBOS T,et al.Transfusion-related acute lung injury (Trali) in a patient with a single lung transplant[J].Br J Haematol,2000,109(3):674-676. [39] VLAAR A P J,KLEINMAN S.An update of the transfusion-related acute lung injury (TRALI):a proposed modified definition and classification scheme definition[J].Indian J Hematol Blood Transfus,2020,36(3):556-558. |